https://www.marketscreener.com/quote/stock/SYNDAX-PHARMACEUTICALS-IN-16725742/news/Syndax-Pharmaceuticals-Presents-Positive-Data-from-Pivotal-AUGMENT-101-Trial-of-Revumenib-in-Relapse-45553311/?utm_source=telegram&utm_medium=social&utm_campaign=share